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 16 
Abstract 17 
Major advances in cancer immunotherapy have dramatically expanded the potential to 18 
manipulate immune cells in cancer patients with metastatic disease to counteract cancer 19 
spread and extend patient lifespan. One of the most successful types of immunotherapy is 20 
the immune checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1, that keep anti-tumour 21 
T cells active. However, not every patient with metastatic disease benefits from this class of 22 
drugs and patients often develop resistence to these therapies over time. Tremendous 23 
research effort is now underway to uncover new immunotherapeutic targets that can be used 24 
in patients who are refractory to anti-CTLA-4 or anti-PD-1 treatment. Here, we discuss 25 
results from experimental model systems demonstrating that modulating the immune 26 
response can negatively affect metastasis formation. We focus on molecules that boost anti-27 
tumour immune cells and opportunities to block immunosuppression, as well as cell-based 28 
therapies with enhanced tumour recognition properties for solid tumours. We also present a 29 
list of challenges in treating metastatic disease with immunotherapy that must be considered 30 
in order to move laboratory observations into clinical practice and maximise patient benefit.31 
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 32 
Introduction 33 
Cancer cells can detach from the primary tumour, intravasate into the blood or lymphatic 34 
system and migrate to distant sites where they extravasate from the blood or lymph vessels 35 
to seed secondary tumour sites. Controlling the spread of cancer and outgrowth at these 36 
secondary sites remains the most challenging aspect of oncology. Across all cancer types, 37 
only around 20% of patients with stage IV metastatic disease survive beyond 5 years of 38 
diagnosis 1. Advances in immunotherapy have started to reverse these dire statistics and, 39 
because of their success in some types of metastatic cancer, immunotherapies have been 40 
heralded as revolutionary drugs in the treatment of metastatic disease. T-cell checkpoint 41 
inhibitors, in particular, such as those that target programmed cell death protein 1 (PD-1), its 42 
ligand PD-L1, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are responsible for 43 
the majority of immunotherapy successes in cancers such as melanoma and lung cancer; 44 
other cancer types exhibit lower numbers of responders with these drugs, which could be 45 
due to the lack of T cell infiltration or (neo)antigen expression 2. Manipulating a cancer 46 
patient’s own T cells has solidified the concept that immune cells can be targeted effectively 47 
for patient benefit. However, cancer immunotherapy has a limited range. We have already 48 
learnt from clinical trials testing anti-CTLA-4 and anti-PD1 that these drugs are largely futile 49 
in eradicating secondary tumours and extending the lifespan of most cancer patients with 50 
metastasis, due to inherent or acquired drug resistance 3. Consequently, alternative 51 
immunotherapeutic approaches are required to counteract metastasis in patients that are 52 
unresponsive to CTLA-4 and/or PD-1/PD-L1 inhibitors. As invasion and metastasis rely 53 
heavily on the pro-tumour and anti-tumour functions of immune cells, understanding the 54 
cellular and molecular processes that underpin the progression of metastatic disease is likely 55 
to offer novel immunotherapy options. In this review, we discuss the advances that have 56 
been made in generating immunotherapeutic alternatives to CTLA-4 and PD-1/PD-L1 in 57 
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experimental model systems of solid tumours, as well as highlighting the challenges in 58 
treating secondary tumours with immunotherapy. 59 
 60 
Enhancing endogenous anti-tumour immunity  61 
In addition to CTLA-4 and PD-1, a number of other T-cell checkpoint inhibitors that might 62 
prove extremely valuable in treating metastatic tumours have emerged over the past years, 63 
such as TIM-3 and LAG-3 (Figure 1) 4. Furthermore, the catalog of inhibitory molecules has 64 
expanded to include receptors exclusively expressed on natural killer (NK) cells 5, several of 65 
which are shared by γδ T cells 6. Given that NK cells are critical in combating metastasis 7, 66 
blocking inhibitory molecules on NK cells, which limit their killing and cytotoxic molecule 67 
production, such as TIGIT and NKG2A, could prove very useful in treating patients with 68 
metastatic disease. Below we outline such T-cell-associated immune checkpoint inhibitors 69 
and NK cell-associated immune checkpoint inhibitors. Employing alternative immune 70 
checkpoint inhibitors to anti-CTLA-4 and anti-PD-1 that activate innate-like and/or adaptive 71 
lymphocytes could provide additional benefit or perhaps even function more effectively than 72 
the standard anti-CTLA-4/PD-1 therapies (Figure 1). 73 
 74 
TIM-3. One of the most promising immune-modulating checkpoints currently under 75 
investigation is T-cell immunoglobulin and mucin domain 3 (TIM-3), encoded by the gene 76 
HAVCR2 8. TIM-3 can be expressed by multiple subsets of T cells including CD8+ and CD4+ 77 
T cells, regulatory T cells and NK cells 9-11, as well as myeloid cells, such as dendritic cells 78 
and macrophages 12-15. In the absence of ligand, TIM-3 recruits the tyrosine kinase LCK to 79 
mediate T-cell activation. However, ligand engagement of TIM-3 is known to disrupt the 80 
immunological synapse, interfere with LCK signalling and induce T-cell apoptosis (reviewed 81 
in 8). The two most well-studied ligands of TIM-3 include galectin-9 and carcinoembryonic 82 
antigen-related cell adhesion molecule 1 (CEACAM1), both of which can be produced by 83 
cancer cells and myeloid cells (reviewed in 8).  84 
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            The expression of TIM-3 is associated with advanced tumour stage and lymph node 85 
metastasis in lung cancer patients 10. In patients with metastatic melanoma, TIM-3 86 
expression is also associated with dysfunctional/exhausted CD8+ T cells and NK cells, and 87 
the inhibition of TIM-3 signalling ex vivo increases the functional capacity of these cells 16,17. 88 
Interestingly, the reversion of patient-derived CD8+ T-cell dysfunction requires dual blockade 89 
of both TIM-3 and PD-1 16. After anti-PD-1 therapy, the expression of TIM-3 increases on 90 
CD4+ and CD8+ T cells in metastatic lung cancer patients and lung cancer mouse models 91 
driven by mutant epidermal growth factor receptor (EGFR) or mutant KRAS18, suggesting 92 
that this molecule is involved in adaptive resistance to PD-1 inhibition. Indeed, the 93 
combinatorial treatment of lung-tumour-bearing CC10-rtTA;Tre-EgfrT790M/L858R mice with anti-94 
PD-1 and anti-TIM-3 extends survival compared with anti-PD-1 blockade alone 18. Similarly, 95 
targeting both PD-1 and TIM-3 in mice bearing transplantable CT26 or MC38 colorectal 96 
cancer cells or B16 melanoma cells slows primary tumour growth 19. In the MMTV-PyMT 97 
mammary tumour model, paclitaxel and anti-TIM-3 blocking antibodies control primary 98 
tumour growth more efficiently than chemotherapy alone, while anti-TIM-3 monotherapy is 99 
ineffective 15. Mammary tumour-infiltrating CD103+ dendritic cells express high levels of TIM-100 
3, whereas the expression of TIM-3 in CD8+ T cells is negligible in this model. These TIM-3-101 
expressing CD103+ dendritic cells play a crucial role in the chemotherapy response, as their 102 
depletion abrogates the response to paclitaxel/anti-TIM-3 treatment. The blockade of TIM-3 103 
or galectin-9 in MMTV-PyMT tumour-bearing mice increases the expression of CXC 104 
chemokine ligand 9 (CXCL9) in CD103+ dendritic cells, which recruits cytotoxic CXC 105 
chemokine receptor 3 (CXCR3)+ CD8+ T cells to tumours 15. Given the importance of TIM-3-106 
expressing T cells and dendritic cells in cancer progression and chemotherapy response, 107 
TIM-3 inhibition might be useful in the metastatic setting to recruit cytotoxic T cells or to 108 
reinvigorate exhausted T cells in immunotherapy-naïve and/or anti-PD-1 refractory patients.  109 
 110 
LAG-3. Lymphocyte Activation Gene 3 (LAG-3) is another checkpoint molecule expressed 111 
on T cells and NK cells; it exerts its inhibitory function by binding to MHC class II and other 112 
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ligands, such as LSECtin (reviewed in 20). A newly discovered LAG-3 ligand produced by 113 
liver and cancer cells — fibrinogen-like protein 1 (FGL1) — has been identified to mediate 114 
antigen-specific T-cell suppression 21. Increased LAG-3 expression on CD4+ and CD8+ T 115 
cells is associated with liver metastasis in mismatch-repair-proficient colorectal cancer. Like 116 
PD-1 and TIM-3, LAG-3 expression is associated with dysfunctional tumour-infiltrating T cells 117 
in mouse models and human metastatic tumours 22-24, and the combination of anti-PD-1 and 118 
anti-LAG-3 treatment delays tumour growth in mice bearing subcutaneous Sa1N 119 
fibrosarcoma cells or MC38 colorectal cancer cells 25. The anti-PD-1/anti-LAG-3 combination 120 
is also highly efficacious in the metastatic IE9mp1 transplantable ovarian cancer model 26,27. 121 
In lung colonisation models of metastasis using 4T1 mammary cells, LAG-3 blockade 122 
accompanied by treatment with immunostimulatory interleukin (IL)-12 reduces tumour growth 123 
more effectively than anti-LAG-3 or IL-12 treatment alone. In this model, tumour control is 124 
mediated by targeting LAG-3-expressing NK cells with anti-LAG-3 antibodies 28.  125 
The expression of LAG-3 is regulated by glycogen synthase kinase-3 (GSK-3), and 126 
attempts at decreasing LAG-3 transcription in T cells and NK cells using a GSK-3β inhibitor 127 
have shown that this is a viable strategy to counteract B16 melanoma growth in the lung 29. 128 
In another approach, instead of blocking LAG-3 signalling, LAG-3 fused to the Fc region of 129 
IgG1 (LAG-3Ig or IMP321) can be used as an MHC-II agonist to activate dendritic cells and 130 
anti-tumour T-cell responses through so-called immunopotentiation. An early phase trial with 131 
metastatic breast cancer patients demonstrated the potency of this molecule in combination 132 
with paclitaxel, where 15 out of 30 women exhibited an objective tumour response 30. Thus, 133 
manipulating LAG-3 in patients with metastasis shows promise. 134 
 135 
B7-CD28 superfamily members. CTLA-4 and PD-1 belong to the B7-CD28 superfamily. 136 
Some of the lesser-known members of this family play a role in primary tumour progression, 137 
suggesting that there could be benefit in targeting these molecules in the metastatic setting. 138 
For example, stimulation of inducible T-cell co-stimulator (ICOS) is required for the anti-139 
tumour efficacy of anti-CTLA-4 in B16 and MC38 primary tumours, by generating an effector 140 
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T helper 1 (TH1)-like population that plays a role in limiting tumour growth 31-33. Targeting V-141 
domain Ig suppressor of T-cell activation (VISTA), which can be expressed by cancer cells or 142 
antigen-presenting cells, delays tumour growth in transplantable models and the transgenic 143 
Tyr::CreERT2;BrafV600E;PtenF/F melanoma model, and shifts the tumour microenvironment 144 
towards anti-tumour immunity 34,35. B7-H3 (also known as CD276) is expressed on cancer 145 
cells and tumour-associated endothelial cells. Targeting B7-H3 with antibody–drug 146 
conjugates reduces metastatic progression, and this effect is independent of adaptive 147 
immune cells, as nude mice were used in these experiments 36. Further experimentation of 148 
inhibitors to these molecules in metastasis models is required to understand whether their 149 
function is similar between primary and secondary tumours. 150 
 151 
TNFR superfamily members. Some data on the importance of the tumour necrosis factor 152 
receptor (TNFR) superfamily in promoting or restricting immunity to tumours exist 37. This 153 
group of molecules comprises largely co-stimulatory molecules that synergise with T-cell 154 
receptor signalling to promote T-cell division. For example, OX40 is upregulated on activated 155 
CD4+ and CD8+ T cells, and an agonistic antibody of OX40 synergises with an inhibitor of 156 
transforming growth factor (TGF)-β to reduce the primary tumour growth of 4T1 mammary 157 
cells as well as spontaneous lung metastasis 38.  158 
CD4+ T cells activate CD40 on antigen-presenting cells, to facilitate the maturation of 159 
these cells, and agonists to CD40 have been used to stimulate CD103+ dendritic cells and 160 
prime tumour-specific T cells in genetically engineered mouse models of pancreatic ductal 161 
adenocarcinoma 39,40. CD40 agonist therapy — either as monotherapy or in combination with 162 
cytokines or anti-PD-1 or agonists of the TNFR member CD137 — counteracts metastasis in 163 
transplantable melanoma, pancreatic, colon and kidney cancer models 41-44, and this 164 
immunotherapy can re-polarise myeloid cells towards an anti-tumour phenotype 41,44. 165 
Similarly, agonists of another TNFR member, CD27, reduce lung tumour burden of 166 
intravenously injected B16 melanoma cells 45. Naïve CD4+ and CD8+ T cells constitutively 167 
express CD27, and its activation by the ligand CD70 on dendritic cells supports T-cell 168 
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priming. CD27 signalling has been found to be necessary to generate robust cytotoxic T cells 169 
46,47, so CD27 agonists might further improve anti-PD-1 or CTLA-4 immunotherapy in cases 170 
where tumour-specific T cells are suboptimal. Other TNFR superfamily members, such as 171 
CD30, GITR, BTLA, are currently not well studied in the metastatic setting. 172 
 173 
TIGIT and CD96. T cell immunoreceptor with Ig and ITIM domains (TIGIT; a co-inhibitory 174 
receptor expressed by T cells and NK cells) and CD96 comprise a pathway analogous to 175 
CTLA-4 with CD28, where they bind the same interacting partner — CD155 — to negatively 176 
regulate NK cell function [reviewed in 48]. Inhibition of TIGIT with neutralising antibodies in 177 
lung colonisation experiments of 4T1 mammary cell lines or B16 melanoma cells or carrying 178 
out the experiments in TIGIT knockout mice reduces lung tumours and extends survival 49. 179 
One study found that anti-TIM-3 was required in Tigit–/– mice to reduce experimental lung 180 
metastasis of B16 cells 50. CD8+ T cells also express TIGIT 51, making it an ideal 181 
immunotherapy target to boost the anti-tumour functions of two cytotoxic cell types. Similarly, 182 
anti-CD96 therapy reduces 4T1 or B16 tumours in the lung and this effect is enhanced by the 183 
addition of anti-CTLA-4, anti-PD-1 or doxorubicin chemotherapy 52. Likewise, Cd96–/– mice 184 
develop fewer experimental lung metastases than wild-type mice after tail vein injection of 185 
B16 cells, and this result is dependent on NK cells and interferon (IFN)γ 53. As both TIGIT 186 
and CD96 bind CD155, targeting both TIGIT and CD96 might be essential to achieve 187 
maximum anti-metastatic benefit 52.  188 
 189 
NKG2A. NKG2A is another putative checkpoint inhibitor for NK cells and CD8+ T cells; its 190 
activation occurs through binding of HLA-E in humans or Qa-1b in mice 54. Blocking NKG2A 191 
using the humanised anti-NKG2A antibody monalizumab increases NK-mediated killing 192 
through antibody-dependent cell-mediated cytotoxicity (ADCC) of mouse lymphoma cells in 193 
vivo; however, the potency of monalizumab in counteracting metastases of solid tumours 194 
remains to be seen 55. Clinical trials are underway examining monalizumab with cetuximab 195 
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(anti-EGFR) in patients with metastatic colorectal or head and neck cancers 196 
(NCT026435509).  197 
 198 
IL-1R8. Interleukin 1 receptor 8 (IL-1R8, also called SIGIRR or TIR8) has been identified as 199 
a checkpoint inhibitor on NK cells. Spontaneous lung metastasis from MN/MCA1 sarcoma 200 
cells is reduced in Il1r8–/– mice when compared with wild-type mice but primary tumour 201 
growth remains unaffected. Similarly, Il1r8–/– mice are protected from liver metastasis of 202 
MC38 cells, and these events are reversed by NK cell depletion 56. 203 
 204 
Cell-based immunotherapies for metastatic disease 205 
T cells, NK cells and dendritic cells can be harvested from either cancer patients or healthy 206 
donors, expanded ex vivo, and then transfused back into cancer patients in the process of 207 
adoptive cell therapy (ACT). Whereas ACT using αβ T cells, γδ T cells or NK cells for the 208 
treatment of haematological malignancies is well documented 5,57,58, evidence for the use of 209 
such approaches to treat metastatic disease of solid tumours is scant. This might be because 210 
of the time it takes to generate these cells, the lack of expression of specific tumour antigens 211 
or a lack of efficacy of the transplanted cells. However, a few examples of the potential of 212 
these strategies to treat metastatic disease do exist. Thus far, ACT of CD8+ T cells into 213 
metastatic melanoma patients has been demonstrated to be the most successful regimen 214 
among these types of immunotherapy [reviewed in 59]. Like checkpoint inhibitors, the efficacy 215 
of ACT might be dependent on high expression of (neo)antigens; however, effective ACT in 216 
breast cancer patients, whose tumours exhibit a much lower mutational burden, has been 217 
documented 60. One advantage of the innate-like lymphocytes, γδ T cells and NK cells is that 218 
they are not restricted by MHC molecules, which bypasses the importance of (neo)antigen 219 
expression. In fact, ACT of γδ T cells has induced complete remission of lung metastasis in a 220 
patient with renal cell carcinoma 61.  221 
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Moreover, αβ T cells, γδ T cells and NK cells can also be genetically modified to 222 
enhance their anti-tumour properties, and several attempts have been made at harnessing 223 
the potent killing abilities of these cells by introducing transgenic T-cell receptors or chimeric 224 
antigen receptors (CARs) [reviewed in 57,62,63]. CAR-T cells are gaining traction in solid 225 
tumours and these cells might be useful for metastatic disease if the correct antigen can be 226 
identified. For example, guanylyl cyclase C (GUCY2C)-targeted CAR-T cells can reduce 227 
CT26 colorectal cancer burden in the lungs of mice and extend survival when compared to 228 
CAR-T-cell control-treated mice 64,65. Human macrophages have also been engineered with 229 
CD3ζ-based CARs similar to T-cell CARs in order to direct the phagocytic activity of these 230 
cells against tumours, and these CAR-Ms reduce the burden of lung tumours by ovarian 231 
SKOV3 cancer cells 66. These HER2-directed CAR-Ms effectively reduced tumour burden 232 
and recruited T-cells and presented antigens to them. The field of cell-based 233 
immunotherapies is rapidly evolving, with various endeavours to make these products more 234 
specific, durable and safe, so that future versions are likely to improve their benefits in the 235 
metastatic setting.  236 
 237 
Inhibiting pro-tumour immune cells and immunosuppression at 238 
metastatic sites 239 
Data from mouse metastasis models have highlighted a critical role for myeloid cells and 240 
some innate lymphocyte populations in metastatic progression. Here, we focus on 241 
monocytes/macrophages, neutrophils, regulatory T cells (TREG) and IL-17-producing γδ T 242 
cells. Since myeloid-derived suppressor cells (MDSCs) encompass both monocytes and 243 
neutrophils that are pathologically activated by tumour-derived factors to suppress anti-244 
tumour immune cells 67, we refrain from using the MDSC nomenclature. Instread, we refer 245 
specifically to monocytes or neutrophils to be more precise about their individual role in 246 
metastasis formation. Information on other cell populations, such as eosinophils, basophils, 247 
mast cells and innate lymphoid cells (ILCs), is scarce in the metastatic setting, prohibiting a 248 
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lengthy discussion on opportunities to target these cells. Further knowledge on these lesser 249 
studied immune cells will expand the potential of targetable pathways. For example, a recent 250 
study found that group 2 ILCs and eosinophils support lung metastasis through suppression 251 
of NK cells, highlighting the cytokines, IL-33 and IL-5 in this process 68. While this section 252 
focuses on the pro-metastatic role of immune cells, it should be noted that the role of these 253 
cells in cancer progression is dynamic and subject to their local microenvironment. Immune 254 
cells, in particular macrophages and neutrophils, are not always pro-tumour – their function 255 
depends on their location, polarization, maturation status and stage of disease. 256 
Macrophages are the best-studied group of immune cells in metastasis. We have 257 
known about their potent ability to support metastasis 69 through angiogenesis 70,71 for nearly 258 
20 years, but these cells drive metastasis via multiple other mechanisms, such as providing 259 
growth factors for disseminated cancer cells as well as immune suppression of anti-tumour T 260 
cells and NK cells [reviewed in 72]. Neutrophils are increasingly being recognised for their 261 
pro-metastatic functions. These cells have been somewhat overlooked or avoided as they 262 
are difficult to manipulate, despite evidence of their involvement in metastasis existing more 263 
than 10 years before the data on pro-metastatic macrophages 73. Like macrophages, 264 
neutrophils can drive metastasis both from the primary tumour site or secondary locations 265 
before and after the arrival of disseminated cancer cells in distant organs [reviewed in 74]. 266 
Although low in number, γδ T cells can be very influential in cancer progression, where they 267 
orchestrate immune responses and modulate endothelial cells at metastatic sites primarily 268 
through the production of the pro-inflammatory cytokine IL-17 75,76. Macrophages, IL-17-269 
producing γδ T cells and neutrophils can even work together to establish a systemic 270 
inflammatory pathway that suppresses CD8+ T cells at the pre-metastatic site and supports 271 
metastasis in p53-deficient mammary tumour models 75,77. Finally, regulatory T (TREG) cells 272 
are known to facilitate metastatic progression by immunosuppression, and to shield cancer 273 
cells from immune detection (reviewed in 78). To interfere with the activity of these pro-274 
metastatic immune cells, three key processes that can be targeted have been identified from 275 
preclinical studies: recruitment, survival and reprogramming (Figure 2) 72.  276 
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 277 
Blocking recruitment of pro-metastatic immune cells. CCR2+ bone-marrow-derived 278 
monocytes are readily recruited to primary and secondary tumours in multiple tumour types 279 
by the chemokine CCL2 79-81. Consequently, the CCL2–CCR2 axis represents one point at 280 
which the accumulation of metastasis-associated macrophages could be prevented82,83. 281 
CCR2 small molecule antagonists are effective in transplantable models of pancreatic cancer 282 
and hepatocellular carcinoma 80,84, suggesting that secondary tumours may also be 283 
susceptible to these drugs. As pro-metastatic γδ T cells also express CCR2 83,85,86, inhibitors 284 
of CCL2 or CCR2 could be beneficial for targeting cancer types that rely on monocytes or γδ 285 
T cells or both. In lung metastasis of MMTV-PyMT tumours, CCR2 signalling regulates 286 
monocyte retention by CCL3 activation of CCR1 87, and CCR1+ cells are also important in 287 
driving colorectal cancer liver metastasis 88, highlighting another point of intervention to 288 
thwart metastasis. CCR5 is a another promising target for macrophages (and cancer cells) in 289 
colorectal cancer liver metastasis, as its inhibition repolarizes macrophages towards an anti-290 
tumoural phenotype 89. In a Phase I trial called MARACON, CCR5 inhibition with the HIV 291 
drug, maraviroc, in patients with metastatic colorectal cancer was well tolerated, and tumours 292 
exhibited reduced proliferation 89. However, there are risks to targeting chemokines, and the 293 
duration of treatment is critical to avoid a rebound effect that leads to increased metastasis, 294 
as is seen in models of breast cancer lung metastasis after anti-CCL2 therapy, where 295 
interruption of treatment releases monoyctes from the bone marrow and accelerates 296 
metastasis formation 90. A new mouse model in which the chemokine receptors CCR1, 297 
CCR2, CCR3 and CCR5 are deleted together has been generated 91. The use of such 298 
models in combination with metastasis models will hopefully shed light on combinatorial 299 
chemokine receptor function for pro-metastatic immune cells and will help to determine the 300 
context in which to target these receptors.  301 
Neutrophils use a different set of chemokine receptors to monocytes/macrophages, 302 
such as CXCR1 and CXCR2. Inhibition of CXCR2 in models of spontaneous metastasis — 303 
such as the KrasG12D;Trp53R172H;Pdx1-Cre (KPC) pancreatic cancer model or the Villin-304 
Page 13 of 48 
CreER;KrasG12D;Trp53F/F;Rosa26N1cd/+ (KPN) colon cancer model — reduces the occurrence of 305 
secondary tumours in the liver without affecting survival 92,93. In the context of liver 306 
metastasis as well as lung metastasis 75, neutrophils suppress CD8+ T-cell responses to help 307 
disseminated cancer cells evade anti-tumour immunity, suggesting that combining neutrophil 308 
targeting with T-cell-based immunotherapy might be better than either approach alone. 309 
Indeed, treatment of pancreatic-tumour-bearing KPC mice with CXCR2 inhibitors and anti-310 
PD-1 antibodies extends survival beyond monotherapy controls 92. 311 
Primary 4T1 mammary tumours can induce the production of CCL17/TARC (thymus- 312 
and activation-regulated chemokine) in the pre-metastatic lung, which guides the recruitment 313 
of CCR4+ TREG cells and cancer cells to this site 94. The TREG cells then protect cancer cells by 314 
inhibiting NK cells, thereby facilitating metastasis formation. Depleting TREG cells, inhibiting 315 
CCR4 and the combined silencing of CCL17 and the TREG master transcription factor FOXP3 316 
in CCR4+ cells reduces the number of metastatic foci in the lung 94. Another way to reduce 317 
the recruitment of TREG cells to pre-metastatic sites in liver and mammary tumour models is 318 
accomplished by reducing CCL22 secretion through miR-34 expression, as CCL22 also 319 
binds to CCR4 on TREG cells to promote their immunosuppressive effects 95. Thus, targeting 320 
chemokine receptors in patients with metastatic disease might overcome 321 
immunosuppressive barriers that are established by certain immune cell populations. 322 
 323 
Neutralising survival factors of pro-metastatic immune cells. The colony stimulating 324 
factor (CSF) family members CSF-1, granulocyte-macrophage (GM)-CSF and granulocyte 325 
(G)-CSF are essential for the development, differentiation and survival of myeloid cells 96. It 326 
is perhaps then not surprising that cancer cells often directly or indirectly upregulate CSF 327 
molecules to promote pro-metastatic macrophages and neutrophils and thus to facilitate 328 
cancer progression. Consequently, targeting these molecules should reduce macrophage or 329 
neutrophil survival and negatively affect metastasis formation. For instance, early studies 330 
using Csf1-knockout mice, in which macrophages are severely depleted, showed that these 331 
cells are required for lung metastasis in MMTV-PyMT mammary tumour-bearing mice 69. 332 
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Subsequently, antibodies and small molecules that target the CSF-1 receptor (CSF-1R) have 333 
been shown to reduce metastasis, such as in the MMTV-HER2 mammary tumour model 97, 334 
and to synergise with chemotherapy 80,98-100. The potency of CSF-1R inhibitors has prompted 335 
many pharmaceutical companies to trial these inhibitors in cancer patients 101. However, anti-336 
CSF-1R therapy has been shown to lead to increased metastasis relative to controls through 337 
an increase in the number of neutrophils mediated by a compensatory increase in serum G-338 
CSF 102 or a reduction in the number of NK cells as a consequence of a decrease in the 339 
myeloid-cell derived NK survival factor IL-15 103. These data suggest that depleting 340 
macrophages completely might not be appropriate in every scenario and that it is important 341 
to understand the nuances of macrophage biology in order to manipulate pro-metastatic 342 
polarisation states. Another point to consider when using CSF-1R inhibitors is their inability to 343 
distinguish bone marrow-derived macrophages from tissue-resident macrophages, since 344 
they have different roles in tumour development and progression and these cells may 345 
function at different stages 104,105. In some cases, however, such as in pancreatic cancer 346 
where bone marrow-derived macrophages play a role in antigen presentation and tissue-347 
resident macrophages produce and remodel extracellular matrix molecules, targeting both 348 
populations might be the best approach to prevent cancer spread 106.  349 
G-CSF is the master regulator of granulopoiesis, and several studies have shown that 350 
inhibition of G-CSF decreases neutrophil-mediated metastasis 75,107,108. GM-CSF is 351 
somewhat redundant to G-CSF in neutrophil regulation; although, its expression is dominant 352 
in certain contexts 109. Thus, data from mouse models indicate that inhibiting G-CSF and GM-353 
CSF in metastatic cancer patients with neutrophilia to lower neutrophil numbers may reduce 354 
secondary tumour formation and/or burden. Since chemotherapy induces neutropenia, 355 
decreased neutrophil numbers is often achieved without neutralising G-CSF or GM-CSF. 356 
Indeed, chemotherapy-induced neutropenia is associated with better outcome in patients 357 
with lung, breast, gastric and colorectal cancer 110-113, supporting the notion of targeting 358 
neutrophils in patients with advanced disease. However, to offset infection and neutropenia, 359 
cancer patients on chemotherapy may be given G-CSF or GM-CSF. Whether these 360 
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recombinant cytokines contribute to disease progression in this context needs further 361 
investigation.  362 
Another controversial cytokine for the potential treatment of cancer is IL-2. IL-2 is not 363 
only important for the survival and function of TREG cells, which have high-affinity IL-2 364 
receptors, but it is also vital for the activation of NK cells and effector T cells 114. IL-2 365 
immunotherapy has shown limited success and severe side effects in clinical trials, which 366 
could be due to the competition of TREG cells and NK cells for cytokines. However, as TREG 367 
cells and NK cells express different IL-2 receptors (IL-2Rα and IL-2Rβ, respectively) efforts 368 
have been made to synthesise chimeric IL-2–IL-2Rβ or mutant IL-2 that preferentially binds 369 
to the IL-2Rβ in order to selectively activate NK cells; these agents show improved anti-370 
tumour action, but have not been well studied in metastatic settings yet 115,116.  371 
 372 
Reprogramming pro-metastatic immune cells. Because of the plasticity of myeloid cells, 373 
the metastasis-promoting phenotype of monocytes, macrophages and neutrophils can be 374 
easily influenced by tumour-derived factors. In the MMTV-PyMT mammary tumour model, 375 
CD4 T cell-derived IL-4, cancer cell-derived vascular endothelial growth factor (VEGF) and 376 
endothelial cell-derived angiopoietin 2 (ANGPT2) have all been shown to modulate the 377 
phenotype of pro-metastatic macrophages to promote lung metastasis 117-119. In the same 378 
model, the metastasis-promoting phenotype of macrophages can be reversed epigenetically 379 
by using the class IIa histone deacetylase (HDAC) inhibitor (TMP195), which increases their 380 
phagocytic ability, reduces primary tumour burden and prevents lung metastasis 120. These 381 
data demonstrate that class IIa HDACs acting on macrophages may enhance the efficacy of 382 
conventional therapies in breast cancer patients. WNT signalling constitutes another pathway 383 
that drives macrophage polarisation towards a pro-metastatic phenotype. Across 16 different 384 
genetically engineered mouse models of breast cancer, WNT genes were found to be 385 
upregulated in mammary tumours driven by the loss of p53. Increased expression of WNT 386 
proteins activated macrophages to secrete IL-1β, which promoted metastasis through 387 
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crosstalk with γδ T cells and neutrophils in the lung; WNT inhibition by administration of 388 
LGK974 – an inhibitor of WNT ligand secretion – re-programmed these macrophages and 389 
reduced metastasis 77. In some cases, however, reprogramming macrophages might not be 390 
enough to counteract metastasis, as cancer cells can harbour alternative methods to avoid 391 
destruction by macrophages. CD47, which functions as a ‘don’t eat me’ signal, can be highly 392 
expressed by cancer cells to subvert phagocytosis by signal-regulatory protein alpha 393 
(SIRPα)-expressing anti-tumour macrophages 121. CD47 is upregulated on circulating 394 
colorectal cancer cells 122, and its inhibition with neutralising antibodies reduces metastasis in 395 
a variety of mouse models and patient-derived xenografts 123-128.  396 
For many years, neutrophils were thought to be short-lived cells that were unable to 397 
respond to tumour-derived factors, but several molecules, such as G-CSF 75,107,129 and TGF-β 398 
93,130,131, have been shown to repolarise these cells towards a pro-metastatic phenotype. In 399 
p53-deficient mammary tumour models, macrophage-expressed IL-1β triggers γδ T cells to 400 
express IL-17, which induces the G-CSF-dependent expansion and polarisation of 401 
neutrophils, which, in turn, suppress the activity of cytotoxic CD8+ T cells 75,77. Consequently, 402 
inhibition of TGF-β, IL-17 and G-CSF reverses the phenotype of neutrophils and promotes 403 
the activity of cytotoxic CD8+ T-cells to subvert metastasis 75,93,129,131. 404 
Finally, as TREG cells are highly abundant in tumours and prevent effector immune 405 
function, their reprogramming towards an effector phenotype could prove a fruitful strategy to 406 
increase tumour immunity and prevent metastasis. Blocking critical receptors on TREG cells, 407 
such as CD25 with antibodies and genetically altering neuropilin-1 (Nrp-1), which are 408 
required to develop and maintain the stability and function of TREG cells, changes these cells 409 
to pro-immune cells that produce IFN-γ 132,133.  410 
Reprogramming any one of these immune cell populations by interfering with the 411 
cytokine cascade would therefore be advantageous in thwarting metastasis.  412 
 413 
Challenges in treating metastatic disease with immunotherapy 414 
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To develop successful immunotherapies for metastatic disease, a number of considerations 415 
that might affect immunotherapy efficacy need to be taken into account. The first 416 
consideration includes the type of cancer and the location of the tumour. Although it might 417 
seem obvious, genetic mutations differ significantly between cancer types, and genetic 418 
mutations affect the immune response. Metastases can differ from their primary tumour in 419 
terms of mutational and immune profiles 134-136, and although there are similarities between 420 
metastases of the same organ from different cancer types, there can also be cancer-specific 421 
variations (Figure 3). For instance, CD8+ T-cell infiltration is equivalent between lung 422 
metastases from colorectal cancer and renal cell carcinoma, but NK cells are more abundant 423 
and prognostic indicators in renal cell carcinoma lung metastasis 137. The immune contexture 424 
of primary and secondary tumours can also be analagous with regards to immunologically 425 
silent or active microenvironments as, across multiple cancer types, immune active primary 426 
tumours are more likely to generate immune active metastases 138. However, the immune 427 
landscape might also very well look different between primary and secondary tumours. 428 
These differences might be dependent on the organ that harbours the secondary tumour(s) 429 
or the increased mutational burden of distant metastases 139-143. Adding to this complexity, 430 
the immune landscape across metastases might not be uniform, with hot and cold tumours 431 
existing within the same patient 140,141,144-146.  432 
Related to this, tissue-specific immunity must also be considered, because the 433 
immune system differs between anatomical locations. Data emerging from anti-PD-1 clinical 434 
trials indicate that checkpoint inhibitors are more beneficial for patients with lung metastasis 435 
than liver metastasis, for example 147-150. In melanoma patients, liver metastases have a 436 
lower density of CD8+ T cells at the tumour margin when compared to metastases in other 437 
organs 150, which could explain the reduced response to PD-1 inhibition at this site. Likewise, 438 
in patients with metastatic prostate cancer, anti-CTLA-4 induces anti-tumour TH1 cell-type 439 
CD4+ T-cell responses in primary tumours, but this same response is absent in bone 440 
metastatic lesions. Instead, the bone marrow tumour microenvironment, which is rich in TGF-441 
β, converts CD4+ T cells into TH17 cells to blunt anti-CTLA-4 immunotherapy at this site 151. 442 
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Combining TGF-β inhibitors with anti-CTLA-4 to generate TH1 CD4+ T cell and CD8+ T-cell 443 
responses can reverse these effects in metastatic lesions. Brain and bone metastasis 444 
represent some of the most challenging tumours to treat, largely due to aberrant 445 
vascularisation at these sites or their immune-specialised status. Bone is a particularly 446 
immune-priviledged site in order to protect and preserve the hematopoietic stem cell 447 
compartment. In breast cancer bone metastasis, the cycle of bone degradation and tumor 448 
growth has been shown to be a critical event in permitting the outgrowth of metastatic cells 449 
from dormancy 152. Therefore, combining immunotherapies with osteoclast inhibitors may be 450 
key in the success of treating bone metastasis. In the case of brain metastasis, the success 451 
of T cell and NK cell based immunotherapies is heavily dependent on these antibodies or 452 
small molecules being able to penetrate the blood brain barrier or reactivate T cells in highly 453 
immunosuppressive cervical lymph nodes 153. Recently, it has emerged that anti-PD-1 and 454 
anti-CTLA-4 therapy in tandem significantly increased intracranial anti-tumour activity in 455 
patients with metastatic melanoma, offering promise for the use of immune checkpoints in 456 
treating brain metastasis 154. However, modulation of T cell trafficking molecules and/or 457 
dendritic cell assistance may be critical to overcome immunesuppression of T cells and NK 458 
cells in brian and bone metastasis.  459 
 Finally, the success of T-cell- and NK cell-based immunotherapy is dependent on the 460 
ability of these immune cells to recognise cancer cells. For example, HLA loss of 461 
heterozygosity (LOH) precludes the presentation of (neo)antigens by cancer cells, and HLA 462 
LOH can be more common in metastatic tumours than in primary tumours 140,155,156. Dormant 463 
cancer cells — non-proliferating malignant cells hiding in distant organs — are another 464 
challenge in immune-cell recognition 157, as MHC-I expression might be downregulated on 465 
these cells 158. In addition to the ability of T cells to recognise cancer cells, the other 466 
components of the cancer immunity cycle — including antigen release, antigen presentation, 467 
T-cell priming, trafficking, tumour infiltration and killing — must be intact in patients for 468 
favourable outcomes of T cell-based therapies 159. If any of these components are missing or 469 
become inactive as a result of cancer evolution, T-cell-based immunotherapies fail or 470 
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become inadequate at controlling metastatic lesions. Moreover, acquired resistance to T-cell- 471 
and NK cell-based immunotherapy may arise after initially providing a strong anti-tumour 472 
response. Some of the mechanisms of aquired resistance have been identified, including 473 
HLA loss as stated above 140,155,156, epigenetic dysfunction of T-cells 160, emergence of 474 
additional immunosuppressive pathways 161, or resistance to IFN-γ via new cancer-specific 475 
mutations 162,163. Thus, inherent and acquired resistance to T-cell- and NK cell-based 476 
immunotherapy is a major challenge.  477 
To overcome these challenges, a deeper understanding of the immune landscape, 478 
genetic mutations, components of the cancer immunity cycle and tissue-specific immunity is 479 
needed to facilitate personalised approaches to immunotherapy in metastatic disease. What 480 
is clear from experimental models and on-going clinical trials is that the immune response to 481 
metastatic lesions can change dramatically over time, and it is not linear. Therefore, future 482 
treatment modalities will need to anticipate how pro-tumour and anti-tumour immune cells 483 
react to first-line immunotherapies, and mitigate roadblocks with additional 484 
immunomodulatory drugs. 485 
 486 
Conclusions 487 
As outlined in this article, a great many new immunotherapeutic targets are on the horizon for 488 
metastatic disease. Possibly, however, the biggest improvement for patients will come from 489 
the use of combination therapies that both boost anti-tumour immunity and attenuate 490 
immunosuppression. Biomarkers arising from the study of anti-PD-1/CTLA-4 non-responding 491 
patients or from those patients who acquire resistance might also identify suitable 492 
immunotherapy targets to re-engage anti-tumour immune activity when anti-PD-1/CTLA-4 493 
approaches become inert. Mechanisms to induce tertiary lymphoid structures and antigen-494 
presenting B cells — two anti-tumour features not well explored in metastasis — could 495 
support effector T-cell responses and complement immunotherapies in metastatic disease, 496 
as seen in patients with melanoma or sarcoma 164-166.  497 
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To optimally exploit these immunotherapies, it will be important to increase our 498 
understanding of the context in which they are most efficacious. These efforts will require 499 
more knowledge regarding the interplay between specific molecules and specific cell types in 500 
the metastatic setting. Choosing the right model is paramount to address this knowledge 501 
gap. Injectable cell lines, such as the B16 melanoma cells, have been instrumental in 502 
immunotherapy discovery, but they fail to represent the full metastatic cascade. The 503 
immunotherapy field will need to adopt or create models that recapitulate the evolution of the 504 
immune response that occurs when tumours are allowed to progress from early stage to late 505 
stage metastatic disease. These models might help to uncover immunotherapy targets that 506 
specifically rewire the pre-metastatic niche, prevent cancer cell seeding or eliminate 507 
established tumours at distant sites. Combining metastasis models with humanised mice 508 
might also be useful to enhance personalised immunotherapies. It is hoped that the 509 
development of these tools will generate new insights into immunotherapeutic intervention for 510 
metastatic disease. 511 
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 1052 
Figure legends 1053 
Figure 1: Inhibitory and stimulatory immune checkpoint molecules regulate the anti-1054 
tumour response at metastatic sites. 1055 
A) In metastatic progression, cancer cells detach from the primary tumour, intravasate into 1056 
the blood or lymphatic system and migrate to distant sites where they extravasate from the 1057 
blood or lymph vessels to seed secondary tumour sites. B) Cancer cells, macrophages and 1058 
other cells at metastatic sites can express a plethora of immunomodulatory proteins to inhibit 1059 
and activate anti-tumour T cells. The binding of these ligands to their cognate checkpoint 1060 
receptors, such as programmed death-ligand 1 (PD-L1) with programmed cell death protein 1061 
1 (PD-1) and galectin-9 or carcinoembryonic antigen-related cell adhesion molecule 1 1062 
(CEACAM1) with TIM-3, dampens T-cell activation and effector anti-tumour T-cell responses. 1063 
Checkpoint molecules such as VISTA, LAG-3 and CTLA-4 are inhibitory receptors that 1064 
deliver negative stimulation signals upon binding to MHC-II, FGL1 and the co-stimulation 1065 
molecules CD80 and CD86. C) Engagement of stimulatory receptors such as OX40, ICOS, 1066 
CD40 and CD27 with their cognate ligand, or agonists that artificially provide these signals, 1067 
drives T cell activation, differentiation and effector responses. Dendritic cells can be activated 1068 
through CD40 and CD70 to induce their maturation and antigen-presenting properties. D) 1069 
Natural killer (NK) cells can be manipulated by cancer cells and myeloid cells that express 1070 
inhibitory ligands to dampen their cytotoxic effector responses. The inhibitory receptors T cell 1071 
immunoreceptor with Ig and ITIM domains (TIGIT) and CD96 both have affinity for CD155, 1072 
which is expressed on many types of cancer cell. NKG2A binds HLA-E on human cells or 1073 
Qa-1b on mouse cells to block NK-cell-mediated killing. These inhibitory and activatory 1074 
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checkpoint pathways can be selectively modulated by blocking or agonist antibodies to 1075 
release the brake on anti-tumour immunity in order to treat or prevent metastatic disease. 1076 
 1077 
Figure 2: Exploiting pro-metastatic immune cell recruitment, survival and re-1078 
programming to counteract metastasis 1079 
Recruitment, survival and re-programming of immune cells to a pro-tumorigenic phenotype at 1080 
distant sites are key processes in the metastatic cascade. A) Primary and secondary 1081 
tumours release chemokines that attract aiding and abetting immune cells to encourage 1082 
metastasis. In many cancers, CCR2+ bone-marrow-derived monocytes are recruited to 1083 
primary and secondary tumours by the chemokine ligand CCL2, where these monocytes 1084 
differentiate into macrophages. Pro-metastatic CXCR2+ neutrophils are recruited by CXCL1, 1085 
CXCL2 or CXCL5, while pro-tumour CCR4+ regulatory T (TREG) cells require CCL17 or 1086 
CCL22. Targeting these chemokine pathways can prevent the accumulation of these cell 1087 
types and reduce metastasis in the liver or lung of colorectal, pancreatic and breast cancer 1088 
mouse models. B) Targeting colony stimulating factor (CSF)-1, granulocyte-macrophage 1089 
(GM)-CSF and granulocyte (G)-CSF affects the pro-metastatic cascade. Tumour-associated 1090 
macrophages (TAMs) secrete interleukin (IL)-1β to activate IL-17-producing γδ T cells, which 1091 
induce immunosuppressive neutrophils through G-CSF. Metastasis-associated macrophages 1092 
(MAM) provide growth factors, survival signals and angiogenic factors at secondary sites to 1093 
support outgrowth of cancer cells. C) The cytokine IL-2 is essential for the survival of pro-1094 
tumour TREG cells as well as the activation of anti-tumour natural killer (NK) cells. Targeting 1095 
selective IL-2 receptors on TREG cells might prevent their accumulation while enabling anti-1096 
tumour NK cells to remain active. D) Tumour-derived factors such IL-4, vascular endothelial 1097 
growth factor (VEGF) and angiopoietin 2 (ANGPT2) can induce pro-tumorigenic 1098 
macrophages, while transforming growth factor (TGF)-β can enhance pro-metastatic 1099 
neutrophils. CD47 functions as a ‘don’t eat me’ signal and can be upregulated on metastatic 1100 
cancer cells to evade immune surveillance and phagocytosis by macrophages. Tumour-1101 
derived WNT ligands induce macrophages to secrete IL-1β, which activates IL-17-producing 1102 
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γδ T cells to drive pro-metastatic neutrophils. Blocking or interfering with the cytokine 1103 
cascade or receptors on these pro-metastatic immune cells could reprogramme them away 1104 
from a pro-tumorigenic phenotype in order to prevent metastatic disease. 1105 
 1106 
Figure 3. Challenges for targeting metastatic tumours. 1107 
Metastatic tumours differ from primary tumours in various ways. Metastases occurring in 1108 
various locations must adapt to the new tissue-specific environment (coloured circles). 1109 
Metastatic tumours can acquire new (epi)genetic mutations, but antigens arising from these 1110 
mutations are not always presented on the surface of cancer cells, thereby preventing T-cell 1111 
recognition. The immune landscape can also be very different between primary and 1112 
secondary tumours, due to varying abundance of specific immune cell populations between 1113 
organs. Finally, immune responses to metastatic lesions might evolve significantly over the 1114 
course of time due to acquired resistance to anti-cancer therapy (chemotherapy, 1115 
radiotherapy, targeted therapy, etc) by secondary tumours.  1116 
